©TheCanadian Journal ofUrology™: International Supplement, April 2014
41
Al-AsaaedandWinquist
18.Reese DM, Small EJ. Secondary hormonal manipulations
in hormone refractory prostate cancer.
Urol Clin North Am
1999;26(2):311-321.
19.Labrie F, DupontA, GiguereM et al. Benefits of combination
therapywith flutamide in patients relapsing after castration.
Br JUrol
1988;61(4):341-346.
20.Schellhammer PF, Davis JW.An evaluationof bicalutamide in
the treatment of prostate cancer.
ClinProstateCancer
2004;2(4):
213-219.
21.SuzukiH,OkiharaK,MiyakeHetal.AlternativeNonsteroidal
Antiandrogen Therapy for Advanced Prostate Cancer That
RelapsedAfterInitialMaximumAndrogenBlockade.
JUrol
2008;
180(3):921-927.
22.Scher HI, Beer TM, Higano CS et al. Antitumour activity of
MDV3100 in castration-resistant prostate cancer: a phase 1/2
study.
Lancet
2010;375(9724):1437-1446.
23.SingerEA,GolijaninDJ,MiyamotoH,MessingEM.Androgen
deprivationtherapyforprostatecancer.
ExpertOpinPharmacother
2008;9(2):211-228.
24.Wilkins A, Shahidi M, Parker C et al. Diethylstilbestrol in
castration-resistantprostatecancer.
BJU International
2012;110(11
Pt B):E727-E735.
25.DawsonNA, ConawayM,Halabi S et al.Arandomized study
comparing standard versus moderately high dose megestrol
acetate for patients with advanced prostate carcinoma.
Cancer
2000;88(4):825-834.
26. IversenP.Antiandrogenmonotherapy: indicationsandresults.
Urology
2002;60(Suppl 3):64-71.
27.NeerajA, Nicholas JV. Secondary hormonalmanipulations in
the treatment of castration refractory prostate cancer.
BJU Int
2011;108(2):227-228.
28.Niraula S, Tannock IF. Broadening horizons in medical
management of prostate cancer.
Acta Oncol
2011;50(Suppl 1):
141-147.
29.Vis AN, Schröder FH. Key targets of hormonal treatment of
prostatecancer.Part1: theandrogenreceptorandsteroidogenic
pathways.
BJU Int
2009;104(4):438-448.
30.Kelly WK, Scher HI. Prostate specific antigen decline after
antiandrogenwithdrawal: theflutamidewithdrawalsyndrome.
JUrol
1993;149(3):607-609.
31.Garcia JA, Rini BI. Castration-resistant prostate cancer: many
treatments, many options, many challenges ahead.
Cancer
2012;118(10):2583-2593.
32.SmallEJ,HalabiS,DawsonNAetal.Antiandrogenwithdrawal
alone or in combination with ketoconazole in androgen-
independentprostatecancerpatients: aphase III trial (CALGB
9583).
JClinOncol
2004;22(6):1025-1033.
33.NakabayashiM, XieW, ReganMM, JackmanDM, Kantoff PW,
OhWK.Responsetolow-doseketoconazoleandsubsequentdose
escalation tohigh-doseketoconazole inpatientswithandrogen-
independentprostate cancer.
Cancer
2006;107(5):975-981.
34.GarcíaR,Duque,Castellsague,PérezG,Stricker.Acohortstudy
on theriskofacute liver injuryamongusersofketoconazoleand
other antifungal drugs.
Br JClinPharmacol
1999;48(6):847-852.
35.Committee onMedicinal Products forHumanUse. European
Medicines Agency recommends suspension of marketing
authorisationsfororalketoconazole:Benefitoforalketoconazole
does not outweigh risk of liver injury in fungal infections.
London: EuropeanMedicinesAgency; 2013.
36.Harshman LC, Taplin ME. Abiraterone acetate: targeting
persistentandrogendependence incastration-resistantprostate
cancer.
AdvTher
2013;30(8):727-747.
37
.
-
Enzalutamide-Halted-Early-After-Meeting-Endpoints(accessed
27December 2013).
